STRATA Skin Sciences, Inc.
(NASDAQ: SSKN)

Strata Skin Sciences, Inc., formerly MELA Sciences, Inc., is a medical device company. The Company is engaged in designing and developing software-driven technology for the early detection of skin cancer. The Company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The Company's products include the XTRAC laser and VTRAC excimer lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. The Company is focused on the commercialization of its product, the MelaFind System (MelaFind). MelaFind is a non-invasive, point-of-care instrument to aid in the detection of melanoma. The system features a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated algorithms, trained by the Company's database of melanomas and benign lesions.

1.450

-0.010 (-0.68%)
Range 1.450 - 1.475   (1.72%)
Open 1.475
Previous Close 1.460
Bid Price 0.990
Bid Volume 11
Ask Price 1.020
Ask Volume 40
Volume 7,078
Value -
Remark
Delayed prices. Updated at 06 Dec 2025 02:06.
Data powered by
View All Events

About STRATA Skin Sciences

Strata Skin Sciences, Inc., formerly MELA Sciences, Inc., is a medical device company. The Company is engaged in designing and developing software-driven technology for the early detection of skin cancer. The Company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The Company's products include the XTRAC laser and VTRAC excimer lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. The Company is focused on the commercialization of its product, the MelaFind System (MelaFind). MelaFind is a non-invasive, point-of-care instrument to aid in the detection of melanoma. The system features a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated algorithms, trained by the Company's database of melanomas and benign lesions.

Loading Chart...

Please login to view stock data and analysis